Chen Yue, Li Liang, Qian Xiaoxing, Ge Yongsheng, Xu Geliang
Anhui Medical University, No. 81 Meishan Road, Hefei 230032, China; Anhui Provincial Hospital, No. 17 Lujiang Road, Hefei 230001, China; Department of General Surgery, Hefei Second People's Hospital, No. 246 Heping Road, Hefei 230011, China.
Department of General Surgery, Hefei Second People's Hospital, No. 246 Heping Road, Hefei 230011, China.
Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):190-196. doi: 10.1016/j.clinre.2016.09.010. Epub 2017 Jan 5.
Tripartite Motif Containing 11 (TRIM11), a member of TRIM proteins is overexpressed in gliomas and lung cancer. However, the role of TRIM11 in hepatocellular carcinoma (HCC) is unknown.
Herein, we aimed to investigate the expression and clinical significance role of TRIM11 in HCC.
In this study, our data showed significant higher TRIM11 in HCC tissues (n=117) than in the matched non-tumor liver (NTL) tissues (P<0.01). In consistent with above data, we also found TRIM11 protein expression was significantly increased compared with the matched NTL (P<0.01) by immunohistochemistry analysis. Additionally, our results showed that TRIM11 protein expression in HCC tissues was significantly associated with pathological grade (P<0.01), tumor postoperative metastasis (P=0.031), recurrence (P=0.022), and serum a-fetoprotein (AFP) (P<0.01). Moreover, patients' survival was negatively correlated with TRIM11 protein expression. Furthermore, we found that TRIM11 protein was an independent prognostic factor for disease-free (P<0.01) and overall survival (P<0.01) in HCC patients.
Our data showed that TRIM11 expression was significantly elevated in HCC tissues. The overexpression of TRIM11 is closely associated with HCC progression and poor survival of the patients, indicating TRIM11 is a potential therapeutic target for HCC patients.
含三联基序蛋白11（TRIM11）是TRIM蛋白家族成员之一，在神经胶质瘤和肺癌中过表达。然而，TRIM11在肝细胞癌（HCC）中的作用尚不清楚。
在此，我们旨在研究TRIM11在HCC中的表达及其临床意义。
在本研究中，我们的数据显示，HCC组织（n = 117）中的TRIM11显著高于配对的非肿瘤肝（NTL）组织（P < 0.01）。与上述数据一致，我们通过免疫组织化学分析还发现，与配对的NTL相比，TRIM11蛋白表达显著增加（P < 0.01）。此外，我们的结果表明，HCC组织中TRIM11蛋白表达与病理分级（P < 0.01）、肿瘤术后转移（P = 0.031）、复发（P = 0.022）和血清甲胎蛋白（AFP）（P < 0.01）显著相关。此外，患者的生存率与TRIM11蛋白表达呈负相关。此外，我们发现TRIM11蛋白是HCC患者无病生存（P < 0.01）和总生存（P < 0.01）的独立预后因素。
我们的数据表明，TRIM11在HCC组织中的表达显著升高。TRIM11的过表达与HCC进展及患者的不良生存密切相关，表明TRIM11是HCC患者潜在的治疗靶点。
